OraSure Technologies (OSUR) to Release Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. OraSure Technologies has set its Q1 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. The company had revenue of $75.88 million for the quarter, compared to analysts’ expectations of $74.13 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. OraSure Technologies’s revenue for the quarter was down 38.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.21 earnings per share. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

Shares of OSUR opened at $5.49 on Monday. The firm has a 50-day simple moving average of $6.18 and a two-hundred day simple moving average of $6.81. The stock has a market cap of $420.04 million, a PE ratio of 7.63 and a beta of 0.23. OraSure Technologies has a 1-year low of $4.38 and a 1-year high of $8.45.

Wall Street Analysts Forecast Growth

OSUR has been the subject of a number of research analyst reports. Evercore ISI lowered their price objective on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. StockNews.com upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.